1. Large-Scale SARS-CoV-2 Testing Utilizing Saliva and Transposition Sample Pooling.
- Author
-
Patterson JR, Cole-Strauss A, Kuhn N, Mercier C, Kochmanski J, Gerlach JA, LeVeque RM, Neugebauer KA, Conner KN, Gomez J, Hennes MG, Thompson KE, Rytlewski DL, Bigwood CC, Scharmen A, Simjanovski G, Riley C, Donaldson J, Yasin D, Kouja N, Contejean Z, Burnett M, Aminova S, Yawson NA, Singh SB, Alian OM, Broeker CD, Zaluzec EK, ONeill M, Puschner B, Sousa A, Bix L, Jespersen B, Holzman C, Mitchell J, Julien R, Askin Y, Barnes D, Durshanpalli P, Krum D, Weber R, Patterson M, Anderson B, Hunt R, O'Brien B, Umstead A, Beck JS, Vega IE, Sortwell CE, and Lipton JW
- Subjects
- COVID-19 Testing, Humans, Reproducibility of Results, Saliva, Specimen Handling, COVID-19 diagnosis, SARS-CoV-2
- Abstract
Identification and isolation of contagious individuals along with quarantine of close contacts, is critical for slowing the spread of COVID-19. Large-scale testing in a surveillance or screening capacity for asymptomatic carriers of COVID-19 provides both data on viral spread and the follow-up ability to rapidly test individuals during suspected outbreaks. The COVID-19 early detection program at Michigan State University has been utilizing large-scale testing in a surveillance or screening capacity since fall of 2020. The methods adapted here take advantage of the reliability, large sample volume, and self-collection benefits of saliva, paired with a cost-effective, reagent conserving two-dimensional pooling scheme. The process was designed to be adaptable to supply shortages, with many components of the kits and the assay easily substituted. The processes outlined for collecting and processing SARS-CoV-2 samples can be adapted to test for future viral pathogens reliably expressed in saliva. By providing this blueprint for universities or other organizations, preparedness plans for future viral outbreaks can be developed.
- Published
- 2022
- Full Text
- View/download PDF